ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

brexanolone

Also written as “SAGE-547”, “Brexanolone” and “LPCN 1154A”.

Its studies are mostly in Depression, Postpartum · Status Epilepticus · Tinnitus · Respiratory Distress Syndrome · Essential Tremor, led by 2 companies.

Drug pageBrexanolone: every studyAll 27 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Feb 14, 202014 company-led studies, 1 open or runningNext primary completion: Aug 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Supernus Pharmaceuticalsits history only120 open or runningphase 4since Feb 14, 2020Jan 28, 2014none ahead
Lipocine21 open or runningphase 3since May 13, 2025May 13, 2025Aug 2027phase 3 · NCT07822321

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Lipocine only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2017Named brexanoloneINNProposed as its International Nonproprietary Name in WHO's List 117 · before, SAGE-547, LPCN 1154A
  2. May 13, 2025First study: phase 3 study in Depression, PostpartumFirst studyNCT06979544 · 90 enrolled · United States
  3. Sep 10, 2026Phase 3 study in Depression, PostpartumNCT07822321 · 120 planned · United States

Ahead

  1. Aug 2027Primary completion: phase 3 study in Depression, PostpartumNCT07822321

TargetBeta

“GABA-A receptor; anion channel positive allosteric modulator”ChEMBL 37, by rule

Other programs on the same 16 targets

ProgramCompanyFurthest phaseStudies
MidazolamruleEli Lillyphase 497
ciprofolruleHaisco Pharmaceutical Groupphase 436
AlprazolamruleViatrisphase 435
DiazepamruleAcorda Therapeuticsphase 39

Studies

All 2 Lipocine leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07822321Depression, Postpartum · United States3RecruitingAug 2027120
NCT06979544Depression, Postpartum · United States3CompletedJan 16, 202690

How it is read

Names in the registry

  • “SAGE-547”, 5 entries
  • “Brexanolone”, 4 entries
  • “LPCN 1154A”, 2 entries
  • “SAGE-547 90 μg/kg/h”, 2 entries
  • “SAGE-547 60 μg/kg/h”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.